Working with Astellas/Medivation, I designed the correlative studies and am the central pathologist for a nationwide phase II trial of enzalutamide (an androgen receptor inhibitor) or placebo in men with low risk prostate cancer who are electing to delay curative surgical or radiation treatment (“active surveillance”). NCT02799745, IRB HUM00112108, opened Spring of 2016.
I am also the pathology and biomarker lead for a trial comparing standard androgen deprivation therapy (ADT) versus ADT + palbociclib (a cyclin dependent kinase inhibitor) for men with newly diagnosed metastatic prostate cancer. This trial is led by Dr. Maha Hussein at UM, and was funded through the Prostate Cancer Foundation. Correlative biomarker studies will be performed in my lab through Taubman Institute support. NCT02059213, HUM00082715, completing accrual in the Fall of 2016).